ArticleAnesthesia and analgesia2026
Dexmedetomidine Preemptive Analgesia on Intra- and Postoperative Pain in Noncardiac Surgery: A Randomized, Double-Blind, Controlled Study.
Article in Anesthesia and analgesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInadequate pain management affects over half of the 230 million major surgeries performed annually. Preemptive analgesia aims to prevent peripheral and central sensitization. Dexmedetomidine (DEX) offers non-opioid analgesia and opioid-sparing effects. This study evaluated the efficacy of preemptive DEX using the nociception index (NOX) for objective intraoperative monitoring and assessed its impact on perioperative outcomes.
methodsIn this single-center, double-blind, randomized controlled trial, 220 eligible patients were assigned to receive either intravenous DEX (1.5 µg·kg-1·h-1) (DEX group) or placebo (normal saline) (PO group) from 15 minutes before anesthesia induction until 15 minutes post-induction. The co-primary outcomes were the intraoperative NOX compliance rate (mean NOX ≤60 during nociceptive stimulation) and the incidence of moderate-to-severe postoperative pain (pNRS > 3) at 0, 24, 48 hours, and 7 days. Secondary outcomes included hemodynamic parameters, postoperative nausea and vomiting (mPONV), dizziness, analgesic consumption, and safety events.
resultsThe DEX group demonstrated a significantly higher NOX compliance rate compared to the placebo group (98/108, 90.7% vs 14/112, 12.5%; P <.001). The incidence of NRS>3 was significantly lower in the DEX group at all postoperative time points (3/108, 2.8% vs 29/112, 25.9% at 0 hour; 6/108, 5.6% vs 33/112, 29.5% at 24 hours; 1/108, 0.9% vs 19/112, 17% at 48 hours; 0/108, 0% vs 6/112, 5.4% at 7 d; P = .000). DEX also reduced rescue opioid consumption (z = -2.428, P = .004), decreased mPONV (z = -4.901, P = .001), and improved hemodynamic stability. Safety profiles were favorable in DEX group.
conclusionPreemptive analgesia with DEX significantly improves both intraoperative nociceptive control as objectively measured by the NOX and postoperative pain control. It validates the role in optimizing perioperative analgesia and enhancing recovery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.